TGF-β was also shown to convert iCAFs into myCAFs, via antagonism of the JAK/STAT pathway and downregulation of IL-1R1 expression.118 The presence of interconvertible myCAFs and iCAFs in PDAC is supported by Ohlund et al.114 Biffi et al.118 therefore suggest drug combinations targeting both iCAFs and myCAFs, to decrease tumour-promoting inflammation and deplete the dense stroma impeding drug delivery. Here, TGFB1 is linked to neoplasm.